LBA4 Background: In KEYNOTE-024, pembro significantly improved PFS (primary end
point) and OS (secondary end-point) over chemo as first-line therapy for metastatic NSCLC …

Background Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with
survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced …

Background In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival
(OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell …

Background: Pembro significantly improved OS vs chemo as first-line therapy in pts with PD-
L1–positive locally advanced/metastatic NSCLC without EGFR/ALK alterations after median …

Background The efficacy and safety of the anti–programmed death ligand 1 (PD-L1)
monoclonal antibody atezolizumab, as compared with those of platinum-based …

Abstract Background PD-L1/PD-1 inhibitors (CPI) as monotherapy or combined with
platinum-based doublet chemo (±bevacizumab) are 1L tx options in metastatic NSCLC, with …

9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for
treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy …

Purpose To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-
L1 antibodies for treatment of patients with advanced or refractory cancer. Results Fifty-one …

Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …

Background KEYNOTE-024 (ClinicalTrials. gov, NCT02142738) is a multicenter,
international, phase 3, randomized, open-label, controlled trial of treatment with the anti‒PD …